PMID-18577961 – Selank Immunomodulatory Effects in Anxiety Patients
Uchakina ON et al., "Immunomodulatory Effects of Selank in Patients with Anxiety-Asthenic Disorders," Zh Nevrol Psikhiatr Im S S Korsakova, 2008;108(5):71-75.
Quick Reference
| Property | Value |
|---|---|
| PMID | 18577961 |
| DOI | — |
| Year | 2008 |
| Journal | Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova |
| Study Type | Observational (human clinical) |
| Evidence Level | III |
| Sample | Patients with anxiety-asthenic disorders |
| Peptide(s) Studied | Selank |
Key Findings
- In patients with anxiety-asthenic disorders, Selank (10⁻⁷ M) completely suppressed IL-6 gene expression in peripheral blood of depressed patients but not in healthy controls, indicating disease-state-specific immunomodulation
- A 2-week in vivo Selank treatment course altered the Th1/Th2 cytokine balance in patients, shifting immune profiles toward normalization
- Results confirm Selank functions as an immunomodulator in clinical populations, not only in preclinical models, bridging its tuftsin-derived immunoactive heritage to therapeutic application
Study Design
Patients diagnosed with anxiety-asthenic disorders received Selank treatment for 2 weeks. Peripheral blood samples were collected to assess cytokine gene expression (including IL-6) and Th1/Th2 balance markers ex vivo (at 10⁻⁷ M concentration) and in vivo (after the treatment course). Healthy controls were included for comparison of ex vivo effects.
Limitations
- Published in a Russian-language journal with limited international visibility and indexing
- Small sample size limits statistical power and generalizability
- Not a placebo-controlled randomized trial; observational design introduces potential bias
- Ex vivo concentration effects may not directly correspond to in vivo pharmacodynamics
Clinical Relevance
This is one of the few human clinical studies demonstrating Selank's immunomodulatory effects in patients, supporting its dual anxiolytic-immunomodulatory profile. The disease-state-specific suppression of IL-6 is particularly relevant for patients with comorbid anxiety and inflammatory conditions.
Related
#research #observational #evidence-level-III